Win for Takeda in second US Actos trial
This article was originally published in Scrip
Executive Summary
Judgment has been entered in favor of Takeda in the second case to come to trial in the US regarding claimed links between bladder cancer and the Japanese company's diabetes drug Actos (pioglitazone).